Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies And Novartis

By Zacks Investment ResearchStock MarketsJul 21, 2019 11:20PM ET
www.investing.com/analysis/the-zacks-analyst-blog-highlights-abbott-netflix-philip-morris-united-technologies-and-novartis-200442706
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies And Novartis
By Zacks Investment Research   |  Jul 21, 2019 11:20PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

For Immediate Release

Chicago, IL –July 22, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott (NYSE:ABT) , Netflix (NASDAQ:NFLX) , Philip Morris (NYSE:PM) , United Technologies (NYSE:UTX) and Novartis (NYSE:NVS) .

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Abbott, Netflix and Philip Morris

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott, Netflix and Philip Morris. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Outperform-rated Abbott’s shares have gained +38.6% over the past year, significantly outperforming the Zacks Medical Products industry, which has increased +6.4% over the same period. Abbott exited second quarter 2019 with better-than-expected earnings. However, revenues lagged the estimates.

The Zacks analyst likes the strong and consistent EPD and Medical Devices performance. The company has been stealing the limelight within Diabetic Care on growth with FreeStyle Libre. This apart, synergies from Alere consolidation in the form of Rapid Diagnostics have been driving growth. Within Structural Heart, worldwide uptake of MitraClip therapy improves further.

Meanwhile, the company’s emerging market performance has been promising. Consequently, Abbott has raised its full-year guidance. On the flip side, sluggish Rhythm Management arm in the United States continues to dent growth. Increasing currency headwinds is another downside.

(You can read the full research report on Abbott here >>>).

Shares of Netflix have gained +21.5% year to date, underperforming the Zacks Broadcast Radio and Television industry’s rally of +22.8% during the same period. Netflix’s second-quarter 2019 subscriber additions rate faltered primarily due to price hike in a number of regions and a weak content slate.

The company also blamed the record addition (9 million) of subscribers in the first quarter which resulted in a pull-forward effect for the decline. Although Netflix provided an optimistic third-quarter view, The Zacks analyst thinks the streaming giant will face hard times due to increasing competition in the video streaming space.

However, Netflix believes that lost shows will free-up its budget that it can then spend on original content. Moreover, partnerships with Telefonica (MC:TEF), KDDI, AT&T (NYSE:T), Comcast (NASDAQ:CMCSA), DISH, Verizon (NYSE:VZ), Charter, Altice, T-Mobile and Sky bode well for the streaming platform.

(You can read the full research report on Netflix here >>>).

Philip Morris’ shares have gained +4.1% in the past three months, outperforming the Zacks Tobacco industry, which has declined -1.1% over the same period. The Zacks analyst thinks sturdy bottom-line trend along with efficient pricing and gains from growth of IQOS in the RRPs arena has been boosting the stock.

These upsides made a positive impact on second-quarter results, wherein earnings and revenues beat expectations. Also, earnings improved year on year. Further, management raised its view for 2019. The company is on track to bolster the RRPs space and plans to invest nearly $400 million in this arena in 2019.

However, persistent softness in the cigarette unit is weighing on Philip Morris’ top-line performance. Cigarette shipment volumes are expected to continue declining in 2019. Conventional cigarettes are being weighed down by stringent policies and fading consumer interests. Moreover, unfavorable currency movements are a threat.

(You can read the full research report on Philip Morris here >>>).

Other noteworthy reports we are featuring today include United Technologies and Novartis.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



Netflix, Inc. (NFLX): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

United Technologies Corporation (UTX): Free Stock Analysis Report

Philip Morris International Inc. (PM): Free Stock Analysis Report

Original post

Zacks Investment Research
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies And Novartis
 

Related Articles

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies And Novartis

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email